Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 29:12:729251.
doi: 10.3389/fimmu.2021.729251. eCollection 2021.

COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis

Clio Bilotta  1 , Giulio Perrone  1 , Valeria Adelfio  2 , Giovanni Francesco Spatola  3 , Maria Laura Uzzo  3 , Antonina Argo  1 , Stefania Zerbo  1
Affiliations

COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis

Clio Bilotta et al. Front Immunol. .

Abstract

Introduction: The World Health Organization declared the coronavirus disease 2019 (COVID-19) pandemic on March 11, 2020. Two vaccine types were developed using two different technologies: viral vectors and mRNA. Thrombosis is one of the most severe and atypical adverse effects of vaccines. This study aimed to analyze published cases of thrombosis after COVID-19 vaccinations to identify patients' features, potential pathophysiological mechanisms, timing of appearance of the adverse events, and other critical issues.

Materials and methods: We performed a systematic electronic search of scientific articles regarding COVID-19 vaccine-related thrombosis and its complications on the PubMed (MEDLINE) database and through manual searches. We selected 10 out of 50 articles from February 1 to May 5, 2021 and performed a descriptive analysis of the adverse events caused by the mRNA-based Pfizer and Moderna vaccines and the adenovirus-based AstraZeneca vaccine.

Results: In the articles on the Pfizer and Moderna vaccines, the sample consisted of three male patients with age heterogeneity. The time from vaccination to admission was ≤3 days in all cases; all patients presented signs of petechiae/purpura at admission, with a low platelet count. In the studies on the AstraZeneca vaccine, the sample consisted of 58 individuals with a high age heterogeneity and a high female prevalence. Symptoms appeared around the ninth day, and headache was the most common symptom. The platelet count was below the lower limit of the normal range. All patients except one were positive for PF4 antibodies. The cerebral venous sinus was the most affected site. Death was the most prevalent outcome in all studies, except for one study in which most of the patients remained alive.

Discussion: Vaccine-induced thrombotic thrombocytopenia (VITT) is an unknown nosological phenomenon secondary to inoculation with the COVID-19 vaccine. Several hypotheses have been formulated regarding its physiopathological mechanism. Recent studies have assumed a mechanism that is assimilable to heparin-induced thrombocytopenia, with protagonist antibodies against the PF4-polyanion complex. Viral DNA has a negative charge and can bind to PF4, causing VITT. New experimental studies have assumed that thrombosis is related to a soluble adenoviral protein spike variant, originating from splicing events, which cause important endothelial inflammatory events, and binding to endothelial cells expressing ACE2.

Conclusion: Further studies are needed to better identify VITT's pathophysiological mechanisms and genetic, demographic, or clinical predisposition of high-risk patients, to investigate the correlation of VITT with the different vaccine types, and to test the significance of the findings.

Keywords: COVID-19 vaccine; PF4 antibodies; vaccine adverse effects; vaccine complications; vaccine-related thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
Patient medical history.
Figure 3
Figure 3
Time from vaccination to admission (days).
Figure 4
Figure 4
Onset of symptoms from vaccination.
Figure 5
Figure 5
Symptoms and observations on admission.
Figure 6
Figure 6
Autopsy findings.
Figure 7
Figure 7
Thrombosis sites.
Figure 8
Figure 8
Treatment administration.
See this image and copyright information in PMC

References

    1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta BioMed (2020) 91(1):157–60. doi: 10.23750/abm.v91i1.9397 - DOI - PMC - PubMed
    1. Vermund SH, Pitzer VE. Asymptomatic Transmission and the Infection Fatality Risk for COVID-19: Implications for School Reopening. Clin Infect Dis (2021) 72(9):1493–6. doi: 10.1093/cid/ciaa855 - DOI - PMC - PubMed
    1. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA (2020) 323(18):1775–6. doi: 10.1001/jama.2020.4683 - DOI - PubMed
    1. Available at: https://covid19.who.int/.
    1. Frederiksen LSF, Zhang Y, Foged C, Thakur A. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Front Immunol (2020) 11:1817. doi: 10.3389/fimmu.2020.01817 - DOI - PMC - PubMed

Publication types

MeSH terms